DrugPatentWatch Week in Review
Patent Expirations and Generic Competition This week saw several major blockbuster drugs facing patent expirations, potentially opening the market for […]
Update
Update
DrugPatentWatch Ranked Best Biopharmaceuticals Commercial Business Intelligence Platform
DrugPatentWatch has been ranked the “Best Biopharmaceuticals Commercial Business Intelligence Platform” by Global Health & Pharma News This award is
DrugPatentWatch Ranked Best Biopharmaceuticals Commercial Business Intelligence Platform Read Post »
Updating the DrugPatentWatch Biologics Module
Before the passage of the Biologic Patent Transparency Act DrugPatentWatch’s biologic patent data was cited as a reason why the
Generic Portfolio Management, Partnering with Brands, and Staying Competitive
This is my talk from the 14th Annual Portfolio Planning and Partnership for Generic Conference. I discuss: Identifying generic entry
Generic Portfolio Management, Partnering with Brands, and Staying Competitive Read Post »
Upcoming workshop on generic portfolio management
I’ll be leading a workshop on generic portfolio management, and also giving a talk, at the 14th annual Marcus Evans
Upcoming workshop on generic portfolio management Read Post »
DrugPatentWatch and Abbvie discuss Pharmaceutical Portfolio Management
Come join me and Wendi Lau from Abbvie as we participate in an interactive roundtable discussion on pharmaceutical portfolio management.
DrugPatentWatch and Abbvie discuss Pharmaceutical Portfolio Management Read Post »
Connecting Excipients with Drug Patents – New DrugPatentWatch module
New DrugPatentWatch module connects excipients and drug patents In response to user requests, DrugPatentWatch has added a new database of
Connecting Excipients with Drug Patents – New DrugPatentWatch module Read Post »
Say ‘NO’ to Bad Contracts
Are you tired of having to navigate complicated contracts to access the information you need? Let DrugPatentWatch free you from
DrugPatentWatch featured in Inc Magazine
DrugPatentWatch was featured in a recent article by Inc. Magazine. In their coverage of Mark Cuban’s new pharma company, they cited